G-protein coupled receptor kinase 2 mediates rheumatoid arthritis-induced depression-like behaviors via the hippocampal CRHR1 signaling pathway
- PMID: 40691271
- DOI: 10.1038/s41401-025-01621-8
G-protein coupled receptor kinase 2 mediates rheumatoid arthritis-induced depression-like behaviors via the hippocampal CRHR1 signaling pathway
Abstract
Rheumatoid arthritis with depressive symptoms is frequently encountered in clinic. In this study, we investigated the molecular mechanisms responsible for comorbid depression with rheumatoid arthritis in collagen-induced arthritis (CIA) model mice. We showed that depression-like behaviors were developed at 5 weeks after establishing CIA model. Furthermore, we found that in the hippocampus of CIA mice, G-protein coupled receptor kinase 2 (GRK2) was significantly upregulated, while the expression of its target, corticotropin releasing hormone receptor 1 (CRHR1) was notably decreased, as was the downstream cAMP/PKA/CREB/BDNF signaling. We demonstrated that GRK2 could directly interact with CRHR1, suppressing CRHR1-dependent signaling. Knockdown of hippocampal GRK2 or pharmacological inhibition with CP-25 (35 mg·kg-1·d-1, i.g. for 21 days) could alleviate the depression-like behaviors in CIA mice, whereas GRK2 overexpression induced depression-like behaviors in naive mice. Our study identifies hippocampal GRK2 as a regulator of depression-like behaviors associated with rheumatoid arthritis in CIA model mice, suggesting both a therapeutic target and potential treatment strategy.
Keywords: CP-25; GRK2; depression-like behaviors; hippocampus; neuroinflammation; rheumatoid arthritis.
© 2025. The Author(s) under exclusive licence to The Shanghai Institute of Materia Medica, Chinese Academy of Sciences and Chinese Pharmacological Society.
Conflict of interest statement
Competing interests: The authors declare no competing interests.
Similar articles
-
G protein-coupled receptor kinase 2 as a novel therapeutic target for gland fibrosis of Sjögren's syndrome.Acta Pharmacol Sin. 2024 Dec;45(12):2611-2624. doi: 10.1038/s41401-024-01350-4. Epub 2024 Jul 25. Acta Pharmacol Sin. 2024. PMID: 39054339
-
MiR-134-5p/BDNF/TrkB/CREB signaling pathway involved in the depression-like behaviors in mice following exposure to benzo[a]pyrene.Metab Brain Dis. 2025 May 23;40(5):210. doi: 10.1007/s11011-025-01637-3. Metab Brain Dis. 2025. PMID: 40407953
-
Desloratadine ameliorates paclitaxel-induced peripheral neuropathy and hypersensitivity reactions in mice.Acta Pharmacol Sin. 2024 Oct;45(10):2061-2076. doi: 10.1038/s41401-024-01301-z. Epub 2024 May 24. Acta Pharmacol Sin. 2024. PMID: 38789495
-
The Black Book of Psychotropic Dosing and Monitoring.Psychopharmacol Bull. 2024 Jul 8;54(3):8-59. Psychopharmacol Bull. 2024. PMID: 38993656 Free PMC article. Review.
-
Celecoxib for rheumatoid arthritis.Cochrane Database Syst Rev. 2017 Jun 9;6(6):CD012095. doi: 10.1002/14651858.CD012095.pub2. Cochrane Database Syst Rev. 2017. PMID: 28597983 Free PMC article.
References
-
- Smolen JS, Aletaha D, Barton A, Burmester GR, Emery P, Firestein GS, et al. Rheumatoid arthritis. Nat Rev Dis Prim. 2018;4:18001. - PubMed
-
- Nerurkar L, Siebert S, McInnes IB, Cavanagh J. Rheumatoid arthritis and depression: an inflammatory perspective. Lancet Psychiatry. 2019;6:164–73. - PubMed
-
- Matcham F, Galloway J, Hotopf M, Roberts E, Scott IC, Steer S, et al. The impact of targeted rheumatoid arthritis pharmacological treatment on mental health: a systematic review and network meta-analysis. Rheumatology. 2018;70:1377–91.
-
- Fogarty FA, Booth RJ, Gamble GD, Dalbeth N, Consedine NS. The effect of mindfulness-based stress reduction on disease activity in people with rheumatoid arthritis: a randomised controlled trial. Ann Rheum Dis. 2015;74:472–4. - PubMed
LinkOut - more resources
Full Text Sources
Miscellaneous